Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers.
Identifieur interne : 001B84 ( Ncbi/Merge ); précédent : 001B83; suivant : 001B85Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers.
Auteurs : Rahnuma Wahid [États-Unis] ; Renee Holt [États-Unis] ; Richard Hjorth [États-Unis] ; Francesco Berlanda Scorza [États-Unis]Source :
- Vaccine [ 1873-2518 ] ; 2016.
Descripteurs français
- KwdFr :
- Contrôle de qualité, Department of Health and Human Services (USA), Essais cliniques comme sujet, Grippe humaine (), Humains, Organisation mondiale de la santé, Pandémies (), Pays en voie de développement, Technologie pharmaceutique (organisation et administration), Technologie pharmaceutique (tendances), Vaccins antigrippaux (), Vaccins antigrippaux (normes), Vaccins antigrippaux (ressources et distribution), États-Unis d'Amérique.
- MESH :
- normes : Vaccins antigrippaux.
- organisation et administration : Technologie pharmaceutique.
- ressources et distribution : Vaccins antigrippaux.
- tendances : Technologie pharmaceutique.
- Contrôle de qualité, Department of Health and Human Services (USA), Essais cliniques comme sujet, Grippe humaine, Humains, Organisation mondiale de la santé, Pandémies, Pays en voie de développement, Vaccins antigrippaux, États-Unis d'Amérique.
English descriptors
- KwdEn :
- Clinical Trials as Topic, Developing Countries, Humans, Influenza Vaccines (chemistry), Influenza Vaccines (standards), Influenza Vaccines (supply & distribution), Influenza, Human (prevention & control), Pandemics (prevention & control), Quality Control, Technology, Pharmaceutical (organization & administration), Technology, Pharmaceutical (trends), United States, United States Dept. of Health and Human Services, World Health Organization.
- MESH :
- chemical , chemistry : Influenza Vaccines.
- chemical , standards : Influenza Vaccines.
- chemical , supply & distribution : Influenza Vaccines.
- organization & administration : Technology, Pharmaceutical.
- prevention & control : Influenza, Human, Pandemics.
- trends : Technology, Pharmaceutical.
- Clinical Trials as Topic, Developing Countries, Humans, Quality Control, United States, United States Dept. of Health and Human Services, World Health Organization.
Abstract
With the support of the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services, PATH has contributed to the World Health Organization's (WHO's) Global Action Plan for Influenza Vaccines (GAP) by providing technical and clinical assistance to several developing country vaccine manufacturers (DCVMs). GAP builds regionally based independent and sustainable influenza vaccine production capacity to mitigate the overall global shortage of influenza vaccines. The program also ensures adequate influenza vaccine manufacturing capacity in the event of an influenza pandemic. Since 2009, PATH has worked closely with two DCVMs in Vietnam: the Institute of Vaccines and Medical Biologicals (IVAC) and VABIOTECH. Beginning in 2013, PATH also began working with Torlak Institute in Serbia; Instituto Butantan in Brazil; Serum Institute of India Private Ltd. in India; and Changchun BCHT Biotechnology Co. (BCHT) in China. The DCVMs supported under the GAP program all had existing influenza vaccine manufacturing capability and required technical support from PATH to improve vaccine yield, process efficiency, and product formulation. PATH has provided customized technical support for the manufacturing process to each DCVM based on their respective requirements. Additionally, PATH, working with BARDA and WHO, supported several DCVMs in the clinical development of influenza vaccine candidates progressing toward national licensure or WHO prequalification. As a result of the activities outlined in this review, several companies were able to make excellent progress in developing state-of-the-art manufacturing processes and completing early phase clinical trials. Licensure trials are currently ongoing or planned for several DCVMs.
DOI: 10.1016/j.vaccine.2016.07.046
PubMed: 27484011
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000505
- to stream PubMed, to step Curation: 000505
- to stream PubMed, to step Checkpoint: 000528
Links to Exploration step
pubmed:27484011Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers.</title><author><name sortKey="Wahid, Rahnuma" sort="Wahid, Rahnuma" uniqKey="Wahid R" first="Rahnuma" last="Wahid">Rahnuma Wahid</name><affiliation wicri:level="2"><nlm:affiliation>PATH, Seattle, WA 98109, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>PATH, Seattle, WA 98109</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Holt, Renee" sort="Holt, Renee" uniqKey="Holt R" first="Renee" last="Holt">Renee Holt</name><affiliation wicri:level="2"><nlm:affiliation>PATH, Seattle, WA 98109, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>PATH, Seattle, WA 98109</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Hjorth, Richard" sort="Hjorth, Richard" uniqKey="Hjorth R" first="Richard" last="Hjorth">Richard Hjorth</name><affiliation wicri:level="2"><nlm:affiliation>Global Project Services, Sanibel, FL 33957, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Project Services, Sanibel, FL 33957</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Berlanda Scorza, Francesco" sort="Berlanda Scorza, Francesco" uniqKey="Berlanda Scorza F" first="Francesco" last="Berlanda Scorza">Francesco Berlanda Scorza</name><affiliation wicri:level="2"><nlm:affiliation>PATH, Seattle, WA 98109, USA. Electronic address: fberlanda-scorza@path.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>PATH, Seattle, WA 98109</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27484011</idno><idno type="pmid">27484011</idno><idno type="doi">10.1016/j.vaccine.2016.07.046</idno><idno type="wicri:Area/PubMed/Corpus">000505</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000505</idno><idno type="wicri:Area/PubMed/Curation">000505</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000505</idno><idno type="wicri:Area/PubMed/Checkpoint">000528</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000528</idno><idno type="wicri:Area/Ncbi/Merge">001B84</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers.</title><author><name sortKey="Wahid, Rahnuma" sort="Wahid, Rahnuma" uniqKey="Wahid R" first="Rahnuma" last="Wahid">Rahnuma Wahid</name><affiliation wicri:level="2"><nlm:affiliation>PATH, Seattle, WA 98109, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>PATH, Seattle, WA 98109</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Holt, Renee" sort="Holt, Renee" uniqKey="Holt R" first="Renee" last="Holt">Renee Holt</name><affiliation wicri:level="2"><nlm:affiliation>PATH, Seattle, WA 98109, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>PATH, Seattle, WA 98109</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Hjorth, Richard" sort="Hjorth, Richard" uniqKey="Hjorth R" first="Richard" last="Hjorth">Richard Hjorth</name><affiliation wicri:level="2"><nlm:affiliation>Global Project Services, Sanibel, FL 33957, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Project Services, Sanibel, FL 33957</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Berlanda Scorza, Francesco" sort="Berlanda Scorza, Francesco" uniqKey="Berlanda Scorza F" first="Francesco" last="Berlanda Scorza">Francesco Berlanda Scorza</name><affiliation wicri:level="2"><nlm:affiliation>PATH, Seattle, WA 98109, USA. Electronic address: fberlanda-scorza@path.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>PATH, Seattle, WA 98109</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical Trials as Topic</term><term>Developing Countries</term><term>Humans</term><term>Influenza Vaccines (chemistry)</term><term>Influenza Vaccines (standards)</term><term>Influenza Vaccines (supply & distribution)</term><term>Influenza, Human (prevention & control)</term><term>Pandemics (prevention & control)</term><term>Quality Control</term><term>Technology, Pharmaceutical (organization & administration)</term><term>Technology, Pharmaceutical (trends)</term><term>United States</term><term>United States Dept. of Health and Human Services</term><term>World Health Organization</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Contrôle de qualité</term><term>Department of Health and Human Services (USA)</term><term>Essais cliniques comme sujet</term><term>Grippe humaine ()</term><term>Humains</term><term>Organisation mondiale de la santé</term><term>Pandémies ()</term><term>Pays en voie de développement</term><term>Technologie pharmaceutique (organisation et administration)</term><term>Technologie pharmaceutique (tendances)</term><term>Vaccins antigrippaux ()</term><term>Vaccins antigrippaux (normes)</term><term>Vaccins antigrippaux (ressources et distribution)</term><term>États-Unis d'Amérique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="standards" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="supply & distribution" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Technologie pharmaceutique</term></keywords><keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Technology, Pharmaceutical</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="ressources et distribution" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Technologie pharmaceutique</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Technology, Pharmaceutical</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Developing Countries</term><term>Humans</term><term>Quality Control</term><term>United States</term><term>United States Dept. of Health and Human Services</term><term>World Health Organization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Contrôle de qualité</term><term>Department of Health and Human Services (USA)</term><term>Essais cliniques comme sujet</term><term>Grippe humaine</term><term>Humains</term><term>Organisation mondiale de la santé</term><term>Pandémies</term><term>Pays en voie de développement</term><term>Vaccins antigrippaux</term><term>États-Unis d'Amérique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">With the support of the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services, PATH has contributed to the World Health Organization's (WHO's) Global Action Plan for Influenza Vaccines (GAP) by providing technical and clinical assistance to several developing country vaccine manufacturers (DCVMs). GAP builds regionally based independent and sustainable influenza vaccine production capacity to mitigate the overall global shortage of influenza vaccines. The program also ensures adequate influenza vaccine manufacturing capacity in the event of an influenza pandemic. Since 2009, PATH has worked closely with two DCVMs in Vietnam: the Institute of Vaccines and Medical Biologicals (IVAC) and VABIOTECH. Beginning in 2013, PATH also began working with Torlak Institute in Serbia; Instituto Butantan in Brazil; Serum Institute of India Private Ltd. in India; and Changchun BCHT Biotechnology Co. (BCHT) in China. The DCVMs supported under the GAP program all had existing influenza vaccine manufacturing capability and required technical support from PATH to improve vaccine yield, process efficiency, and product formulation. PATH has provided customized technical support for the manufacturing process to each DCVM based on their respective requirements. Additionally, PATH, working with BARDA and WHO, supported several DCVMs in the clinical development of influenza vaccine candidates progressing toward national licensure or WHO prequalification. As a result of the activities outlined in this review, several companies were able to make excellent progress in developing state-of-the-art manufacturing processes and completing early phase clinical trials. Licensure trials are currently ongoing or planned for several DCVMs.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27484011</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2017</Year><Month>12</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>45</Issue><PubDate><Year>2016</Year><Month>10</Month><Day>26</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers.</ArticleTitle><Pagination><MedlinePgn>5430-5435</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(16)30644-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2016.07.046</ELocationID><Abstract><AbstractText>With the support of the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services, PATH has contributed to the World Health Organization's (WHO's) Global Action Plan for Influenza Vaccines (GAP) by providing technical and clinical assistance to several developing country vaccine manufacturers (DCVMs). GAP builds regionally based independent and sustainable influenza vaccine production capacity to mitigate the overall global shortage of influenza vaccines. The program also ensures adequate influenza vaccine manufacturing capacity in the event of an influenza pandemic. Since 2009, PATH has worked closely with two DCVMs in Vietnam: the Institute of Vaccines and Medical Biologicals (IVAC) and VABIOTECH. Beginning in 2013, PATH also began working with Torlak Institute in Serbia; Instituto Butantan in Brazil; Serum Institute of India Private Ltd. in India; and Changchun BCHT Biotechnology Co. (BCHT) in China. The DCVMs supported under the GAP program all had existing influenza vaccine manufacturing capability and required technical support from PATH to improve vaccine yield, process efficiency, and product formulation. PATH has provided customized technical support for the manufacturing process to each DCVM based on their respective requirements. Additionally, PATH, working with BARDA and WHO, supported several DCVMs in the clinical development of influenza vaccine candidates progressing toward national licensure or WHO prequalification. As a result of the activities outlined in this review, several companies were able to make excellent progress in developing state-of-the-art manufacturing processes and completing early phase clinical trials. Licensure trials are currently ongoing or planned for several DCVMs.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wahid</LastName><ForeName>Rahnuma</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>PATH, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holt</LastName><ForeName>Renee</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>PATH, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hjorth</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Global Project Services, Sanibel, FL 33957, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berlanda Scorza</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>PATH, Seattle, WA 98109, USA. Electronic address: fberlanda-scorza@path.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003906" MajorTopicYN="N">Developing Countries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000600" MajorTopicYN="N">supply & distribution</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011786" MajorTopicYN="N">Quality Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013678" MajorTopicYN="N">Technology, Pharmaceutical</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization & administration</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014483" MajorTopicYN="N">United States Dept. of Health and Human Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Clinical trial implementation</Keyword><Keyword MajorTopicYN="Y">Influenza vaccine manufacturing</Keyword><Keyword MajorTopicYN="Y">Quality management systems</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>06</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>07</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27484011</ArticleId><ArticleId IdType="pii">S0264-410X(16)30644-2</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2016.07.046</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Floride</li><li>Washington (État)</li></region></list><tree><country name="États-Unis"><region name="Washington (État)"><name sortKey="Wahid, Rahnuma" sort="Wahid, Rahnuma" uniqKey="Wahid R" first="Rahnuma" last="Wahid">Rahnuma Wahid</name></region><name sortKey="Berlanda Scorza, Francesco" sort="Berlanda Scorza, Francesco" uniqKey="Berlanda Scorza F" first="Francesco" last="Berlanda Scorza">Francesco Berlanda Scorza</name><name sortKey="Hjorth, Richard" sort="Hjorth, Richard" uniqKey="Hjorth R" first="Richard" last="Hjorth">Richard Hjorth</name><name sortKey="Holt, Renee" sort="Holt, Renee" uniqKey="Holt R" first="Renee" last="Holt">Renee Holt</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B84 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001B84 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:27484011
|texte= Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27484011" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |